[widget-area id='above-title-area']

Ascensia Diabetes Care to Present Data at 76th ADA Scientific Sessions

[widget-area id='below-title-area']
Ascensia Diabetes Care to Present Data at 76th ADA Scientific Sessions
[widget-area id='above-article-area']
[widget-area id='in-article-area']

Ascensia Diabetes Care, a global specialist diabetes care company, will attend the upcoming 76th   Scientific Sessions of the American Diabetes Association (ADA) June 10-14 in New Orleans. This will be the first time the company will attend the ADA Scientific Sessions as Ascensia Diabetes Care, and marks the reappearance of the Contour portfolio of blood glucose monitoring systems.

At this year’s Scientific Sessions, Ascensia will present the new corporation to global healthcare professionals, continuing the legacy of 70-plus years of groundbreaking products for diabetes started by Bayer.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings.

“We are pleased to be returning to the American Diabetes Association’s Scientific Sessions as Ascensia Diabetes Care. We see this as the ideal opportunity to tell the story of our new company and present compelling scientific data for our high quality diabetes care solutions,” said Michael Kloss, CEO of Ascensia Diabetes Care, in a press release.

“The ADA Scientific Sessions are the premier diabetes event in the U.S. and offers a unique opportunity to exchange ideas and learn about significant advances in diabetes research, treatment, and care. Ascensia wants to continue to be a trusted partner in the diabetes community and is dedicated to using innovation to offer new solutions for healthcare professionals and people living with diabetes everywhere,” he said.

During the sessions, the company will present key data regarding the usefulness of its wireless-enabled blood glucose meter called Contour Next One, a system that connects to a mobile device through Bluetooth technology. Ascensia will also present new precision data on its Contour Next Link 2.4 meter, a system that uses Medtronic’s insulin pumps. Both technologies have been CE mark-approved in Europe, and are presently under 510(k) and PMA review by the U.S. FDA.

This year’s ADA Scientific Sessions overlap with the launch in the U.S. of the Powered by Accuracy campaign, in which the company is asking for video shares, and will contribute to the Juvenile Diabetes Research Foundation (JDRF) $1 for each video share toward diabetes research and advocacy. Additionally, suitable contestants from the U.S. may enter a drawing on the campaign website to win a free box of 100 Contour Next test strips.

Diabetes is a group of metabolic diseases characterized by high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst, and increased hunger. If left untreated, diabetes can cause many complications. In 2015, an estimated 415 million people worldwide had diabetes.

At the 76th Scientific Sessions, Ascensia Diabetes Care will present the following data:

  • Usability of a New Blood Glucose Monitoring System (BGMS) with a Mobile App (Poster 81-LB), June 12, General Poster Session – Clinical Therapeutics/New Technology–Glucose Monitoring and Sensing;
  • Accuracy Evaluation of Six Blood Glucose Monitoring Systems Often Used with Insulin Pumps following ISO 15197, Section 6.3 (Poster 898-P), June 12, Session GPS02, General Poster Session;
  • Accuracy of Four Systems for Self-Monitoring of Blood Glucose in the Hands of Patients and Professionals (Poster 887-P), June 12, Session GPS02, General Poster Session.

[widget-area id='below-article-area']

Leave a Comment